No price history available for this symbol yet.
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Sector
Drug Manufacturers - Specialty & Generic
Harbin Gloria Pharmaceuticals Co., Ltd. is a Chinese pharmaceutical enterprise primarily focused on the research, development, manufacturing, and commercialization of various medicinal products within the People's Republic of China. The company's comprehensive portfolio addresses a broad spectrum of therapeutic areas, including cardiac and cerebrovascular health, skeletal muscle system support, and urinary tract conditions. It also provides vitamins and minerals, as well as medications for oncology, endocrine disorders, anti-infective treatments, respiratory ailments, antihistamine purposes, and peptic concerns, among other pharmaceutical goods. Established in 2000, the firm's headquarters are located in Harbin, also situated in the People's Republic of China.
www.gloria.ccNo one on the platform currently holds 002437.SZ.
No tracked institution reports a position in 002437.SZ as of their last filing.
No one on the platform has traded 002437.SZ yet.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| ROIC % | 19.0% | — | — | — | ||
| Rev. Growth % | -12.5% | -6.9% | ||||
| Profit Margin % | 17.6% | 4.8% | 2.1% | |||
| Free Cash Flow Margin % | 11.7% | |||||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2026 | $3.6B | — | $0.42 | $0.42–$0.42 | — | 1 |
| 2027 | $4.1B | +11.2% | $0.48 | $0.48–$0.48 | — | 1 |
| 2028 | $2.3B | -42.5% | $0.09 | $0.09–$0.09 | — | 1 |
| 2029 | $2.4B | +1.4% | $0.11 | $0.11–$0.11 | — | 1 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
| Symbol | Price | Today | Mkt cap | P/E |
|---|---|---|---|---|
| 002437.SZHarbin Gloria Pharmaceuticals Co., Ltd | $3.39 | +1.19% | $7.6B | — |
| 002262.SZJiangsu Nhwa Pharmaceutical Co., Ltd. | $21.61 | -0.18% | $22.0B | — |
| 002332.SZZhejiang Xianju Pharmaceutical Co.,Ltd. | $8.52 | -0.93% | $8.4B | — |
| 002399.SZShenzhen Hepalink Pharmaceutical Group Co., Ltd. | $9.42 | +0.43% | $11.7B | — |
| 002422.SZSichuan Kelun Pharmaceutical Co., Ltd. Class A |
| $40.52 |
| -0.32% |
| $64.5B |
| — |
| 002424.SZGuizhou Bailing Group Pharmaceutical Co., Ltd. | $4.46 | +0.22% | $6.2B | — |
| 002773.SZChengdu Kanghong Pharmaceutical Group Co., Ltd | $19.10 | -0.16% | $17.6B | — |
Source: Financial Modeling Prep · peers by sector/industry